Methodological approaches in application of synthetic lethality screening towards anticancer therapy

Canaani, D.
April 2009
British Journal of Cancer;4/21/2009, Vol. 100 Issue 8, p1213
Academic Journal
A promising direction in the development of selective less toxic cancer drugs is the usage of synthetic lethality concept. The availability of large-scale synthetic low-molecular-weight chemical libraries has allowed HTS for compounds synergistic lethal with defined human cancer aberrations in activated oncogenes or tumour suppressor genes. The search for synthetic lethal chemicals in human/mouse tumour cells is greatly aided by a prior knowledge of relevant signalling and DNA repair pathways, allowing for educated guesses on the preferred potential therapeutic targets. The recent generation of human/rodents genome-wide siRNAs, and shRNA-expressing libraries, should further advance this more focused approach to cancer drug discovery.British Journal of Cancer (2009) 100, 1213–1218; doi:10.1038/sj.bjc.6605000 www.bjcancer.com Published online 24 March 2009


Related Articles

  • Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Mizuarai, Shinji; Kotani, Hidehito // Human Genetics;Dec2010, Vol. 128 Issue 6, p567 

    Synthetic lethal interaction is defined as a combination of two mutations that is lethal when present in the same cell; each individual mutation is non-lethal. Synthetic lethal interactions attract attention in cancer research fields since the discovery of synthetic lethal genes with either...

  • G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Bucher, N.; Britten, C. D. // British Journal of Cancer;2/5/2008, Vol. 98 Issue 3, p523 

    Rigorous quality control steps, termed checkpoints, tightly regulate progression through the cell cycle. DNA-damaging chemotherapy and radiation activate functional cellular checkpoints. These checkpoints can facilitate DNA repair and promote cell death in unrepaired cells. There are at least...

  • Will we cure cancer by sequencing thousands of genomes? Nicholson, Joshua M. // Molecular Cytogenetics (17558166);2013, Vol. 6 Issue 1, p1 

    The promise to understand cancer and develop efficacious therapies by sequencing thousands of cancers has not occurred. Mutations in specific genes termed oncogenes and tumor suppressor genes are extremely heterogeneous amongst the same type of cancer as well as between cancers. They provide...

  • Gene Defective in at Least 50-60 Percent of All Prostate Cancers; Find Key Step in Understanding Basis of This Cancer.  // Ascribe Newswire: Medicine;12/20/2001, p1 

    At least 50 to 60% of all prostate cancers are the result of failure of just one gene, according to a study by researchers at Mount Sinai School of Medicine, published in the December 20, 2001 issue of the journal "Science." This discovery opened the way for the possibility of new means of early...

  • Absence of TSG101 transcript abnormalities in human cancers. Trink, Barry; Pai, Sara I; Spunt, Sheri L; Raman, Venu; Cairns, Paul; Jen, Jin; Gabrielson, Ed; Sukumar, Saraswati; Sidransky, David // Oncogene;5/28/98, Vol. 16 Issue 21, p2815 

    The human TSG101 gene was cloned and mapped to chromosome 11p15, a site suspected to contain a tumor suppressor gene involved in a variety of human cancers. Subsequent investigation described the presence of abnormally spliced transcripts and point mutations of TSG101 in breast cancer. Thus, we...

  • MicroRNAs in Human Embryonic and Cancer Stem Cells. Navarro, Alfons; Monzó, Mariano // Yonsei Medical Journal;9/1/2010, Vol. 51 Issue 5, p622 

    MicroRNAs (miRNAs) are small non-coding RNAs that regulate messenger RNAs at the post-transcriptional level. They play an important role in the control of cell physiological functions, and their alterations have been related to cancer, where they can function as oncogenes or tumor suppressor...

  • Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work? De, Pradip; Carlson, Jennifer H.; Leyland-Jones, Brian; Dey, Nandini // American Journal of Cancer Research;2015, Vol. 5 Issue 9, p2871 

    The CIP2A gene is an oncogene associated with solid and hematologic malignancies [1]. CIP2A protein is an oncoprotein and a potential cancer therapy target [2]. Literature shows that CIP2A inhibits the tumor suppressor protein PP2A [3] which downregulates phophorylation of AKT, a hallmark of...

  • Cancer therapy finds a solid target. Secko, David // CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p246 

    Reports on a study conducted by Roberto Chiarle and colleagues which points the finger at the oncogene signal transducer and activator of transcription 3 (STAT3) as a promising target for the development of a broad anticancer therapy. Information on STAT3; Role played by STAT3 in the...

  • Biomarkers of gene expression: Growth factors and oncoproteins. Brandt-Rauf, Paul W. // Environmental Health Perspectives Supplements;Jun97 Supplement 4, Vol. 105, p807 

    Presents a review of literature on methods for detecting growth factors, oncogene proteins and tumor-suppressor gene proteins in the blood of humans with cancer or are at risk for cancer development. Growth factors; Oncoproteins; Role as extracellular biomarkers of gene expression.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics